Aterovax presents outcomes of its sPLA2 activity check in the PEACE trial Aterovax SA.

Home / angiology / Aterovax presents outcomes of its sPLA2 activity check in the PEACE trial Aterovax SA.

Aterovax presents outcomes of its sPLA2 activity check in the PEACE trial Aterovax SA.

Aterovax presents outcomes of its sPLA2 activity check in the PEACE trial Aterovax SA, a organization developing innovative items for atherosclerosis, today announced data demonstrating that its bloodstream check for secretory phospholipase A2 activity significantly improves cardiovascular risk prediction in sufferers with steady coronary artery disease over a 5 calendar year period, independent of established risk markers, including C-reactive protein. SPLA2 is certainly in a family group of pro-inflammatory enzymes from the development and destabilization of atherosclerotic plaques main active ingredient .S.